Techsomed

Techsomed leverages generative AI to transform ablation therapy, a minimally invasive technique for treating tumors, heart arrhythmias, and chronic pain. The company’s first offering, the BioTraceIO360 software suite, focuses primarily on liver tumor ablation procedures. Leveraging standard medical imaging modalities such as Ultrasound, CT, and MRI, Techsomed empowers physicians with tissue damage prediction, advanced patient-specific treatment planning, and interactive ablation procedure analysis. Techsomed secured FDA De-Novo clearance for its post-ablation tissue response prediction offering, positioning BioTrace as the first and only FDA-cleared solution of its kind. Complemented by a 510K clearance for ablation treatment planning and confirmation, these flagship products lay the foundation for the comprehensive BioTraceIO360 Solution. Operating globally, Techsomed maintains a subsidiary in Germany, housing an advanced R&D center—a spin-off from Fraunhofer, a leading German research institution specializing in imaging software solutions. Additionally, a subsidiary in Japan supports commercialization efforts in the Japanese and other Asian markets.

Techsomed has raised $12.9M in total funding across 5 rounds. The company is currently at the B stage. Key investors include Axil Capital, NextLeap Ventures, Cobro Ventures.

Techsomed was founded in 2012 by Yossi Abu (Founder & CEO).

Techsomed operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, with core technologies in Platforms & Interfaces, Software. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Techsomed is based in Derech Meir Weisgal 2, Rehovot, Israel, Center District.